Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Bayer Schering Pharma Oy

Femme Max 99 ans
Bayer Schering Pharma Oy MAJ Il y a 4 ans

Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) for a maximum of 3 years in women 18 to 35 years of age The main objective of this study is to assess the safety and efficacy of 2 doses of LNG, delivered locally by a new intrauterine contraceptive system suitable for use by women 18 to 35 years of age.

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations